Please assess the completion status of the following clinical trial:

Trial Title: Metabolic Cofactor Supplementation in Alzheimer's Disease (AD) and Parkinson's Disease (PD) Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women diagnosed with Parkinson's Disease (Hoehn Yahr 2-4, age \>18 years) or men and women diagnosed with Alzheimer's Disease. Include patients older than 50 years with mild to moderate Alzheimer's disease according to ADAS-cog (Alzheimer's Disease Assessment Scale-cognitive subscale; ADAS≥12) and the Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB; CDR≤2).~* Patients with stable treatments and clinical course~Exclusion Criteria:~* Inability or unwillingness to give written informed consent~* History of stroke, severe brain trauma, toxic drug exposure~* Neurological examination which indicate to Parkinson-Plus syndrome (i.e., pyramidal, cerebellar and autonomic dysfunction findings and gaze paralysis) for PD~* Uncontrolled Type 1 or type 2 diabetes~* Diarrhea (defined as more than 2 stool per day) within 7 days before enrolment~* Chronic kidney disease with an estimated glomerular filtration rate \<60 ml/min/1.73m2~* Significant cardiovascular co-morbidity (i.e. heart failure, documented coronary artery disease, valvular heart disease)~* Patients with active bronchial asthma~* Patients with phenylketonuria (contraindicated for NAC)~* Patients with histamine intolerance~* Clinically significant TSH level outside the normal range (0.04-6 mU/L)~* Known allergy for substances used in the study~* Concomitant medication use: Self-administration of dietary supplements such as any vitamins, omega-3 products, or plant stanol/sterol products within 1 month; Use of an antimicrobial agent in the 4 weeks preceding randomization~* Active smokers consuming \>10 cigarettes/day~* Alcohol consumption over 192 grams for men and 128 grams for women per week~* Patients considered as inappropriate for this study for any reason (patients unable to undergo MRI study, noncompliance etc.)~* Active participation in another clinical study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment Arm (Type: EXPERIMENTAL): Subjects in active treatment will receive dietary supplementation with N-acetylcysteine, L-carnitine tartrate, nicotinamide riboside, and serine, administered as a mixture.
- Placebo Arm (Type: PLACEBO_COMPARATOR): Subjects will take a mixture of placebo as powder dissolved in water by mouth.

Based on this trial design, predict the completion outcome and termination type (if applicable).